Why AXLRx

Commercial intelligence you can defend in the room.

Competitive, patient, and payer intelligence — scoped to your asset, every figure verified against a live source, delivered in 72 hours.

Commission a brief See a sample

Built to a single standard.

72h

From scope confirmation to delivery

100%

Of figures cited to a live source

Unsourced figures shipped, ever

Brief types, one methodology

The difference

Not prose about the market — decisions your team can act on.

A syndicated report describes the market. An AXLRx brief frames the decisions your launch team has to make — on positioning, on access, on where to compete. Every section answers a named commercial question, scoped to your asset and proposed label, not the category in aggregate.

And every figure is verified against a live source at the point of writing. If it can't be sourced, it doesn't appear.

What we cover

Four brief types.

Each scoped to your asset and verified to a live source.

Brief

Competitive Intelligence

Who controls which cohort, on what evidence.

Read → Brief

Disease Landscape

How the population segments and where it's treated.

Read → Brief

Patient Flow Model

Incidence to eligible, every step sourced.

Read → Brief

Payer & HTA

Coverage criteria and the evidence standard.

Read →

Sample output

Competitive map — NSCLC first line, US.

Illustrative. On a commissioned brief every figure is cited by PMID at the exhibit foot.

IO Agent Competitive Map — NSCLC 1L, US Sample · Illustrative

Agent	PD-L1	mOS	US Coverage	Share
PembrolizumabKeytruda · Merck	≥50% / ≥1%	26.3 mo	Broad	~52%
Nivolumab + IpilimumabOpdivo+Yervoy · BMS	Any	15.6 mo	Broad	~18%
DurvalumabImfinzi · AstraZeneca	Any	47.5 mo	Broad	~12%
[YOUR ASSET][Client] · Confidential	Per label	Pending	Pre-approval	See Ex.7

Sources: FDA prescribing information; KEYNOTE-024 (PMID 27718847), CheckMate-9LA (PMID 34126067), PACIFIC (PMID 28885881). Illustrative for this page.

The standard

Verify or drop.

AXLRx uses none of its own memory as a source. Every figure clears these checks before delivery:

Every claim cited to a live PMID, ClinicalTrials.gov ID, or URL at the point of writing — uncited claims are dropped, not estimated
PubMed metadata fetched live during authoring — model memory mis-attributes authors and journals even on correct identifiers
Numeric cross-check: the figure must appear in the cited source, not merely be consistent with it
An independent audit pass after generation — every link, claim, and number re-checked before delivery

Process

Three steps. No retainer.

STEP 01

Submit your asset

Drug, mechanism, indication, target cohort, geography — five minutes.

STEP 02

Scope confirmed in 24h

We confirm scope, clarify open questions, and lock the delivery window.

STEP 03

Delivered in 72h

A decision-structured PDF, an editable Excel model, and an optional deck — with a readout call.

Questions

What teams ask before commissioning.

Scope

How is this different from a syndicated report?

A syndicated report describes the market. This frames the decisions your team needs to make — every section answers a named commercial question.

Sourcing

Are figures verified or recalled from AI?

Every figure is cited to a live PMID or URL at the point of writing, never from model memory, and numerically cross-checked against the source.

Delivery

How fast?

72 hours from scope confirmation, with a 30-minute readout call. A 48-hour track is available for board deadlines.

Tell us your asset.

Your team has the brief in 72 hours. Scope confirmation takes one call.

Start your request

or read a full sample brief before committing